Want to see AU:ACW full AI Analyst Report?
Top Page
Actinogen Medical
(Sydney:ACW)
Select Model
Select Model
Rating:48Neutral
Price Target:
AU$0.04
▲(5.00% Upside)
Action:Reiterated
Date:08/28/26
The score is held down primarily by weak financial performance—FY2026 revenue dropped to zero, losses expanded, and cash burn deepened, increasing funding risk. Technicals are roughly neutral with mild stabilization signals, providing limited support. Valuation remains challenging due to negative earnings and no indicated dividend yield.
Positive Factors
Focused drug-development platform
A focused small-molecule platform and a lead oral candidate provide a defined development strategy. Success in targeted neurological indications could create a scalable product opportunity, although value remains dependent on clinical and regulatory progress.
Negative Factors
Revenue collapsed to zero
The disappearance of revenue materially weakens financial quality and demonstrates that the company is not currently supported by a dependable commercial revenue stream. This increases reliance on clinical progress and future external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused drug-development platform
A focused small-molecule platform and a lead oral candidate provide a defined development strategy. Success in targeted neurological indications could create a scalable product opportunity, although value remains dependent on clinical and regulatory progress.
Read all positive factors
Actinogen Medical (ACW) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$156.60M
Dividend YieldN/A
Average Volume (3M)6.03M
Price to Earnings (P/E)―
Beta (1Y)0.32
Revenue GrowthN/A
EPS Growth5.88%
CountryAU
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,728,479,000
10 Day Avg. Volume4,755,726
30 Day Avg. Volume6,028,147
Financial Highlights & Ratios
PEG Ratio1.10
Price to Book (P/B)4.83
Price to Sales (P/S)0.00
P/FCF Ratio-5.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.08Price Target Upside100.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$38.50M
Actinogen Medical Business Overview & Revenue Model
Company Description
Actinogen Medical Limited is an Australian biotechnology company dedicated to developing treatments for neurological and neuropsychiatric disorders linked to imbalanced brain cortisol levels. Their lead product, Xanamem, an inhibitor of the 11ß-HS...
Actinogen Medical Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
22
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 5.49M | 9.93M | 4.89M | 3.64M |
| Gross Profit | -419.27K | 5.49M | 9.93M | 4.48M | 3.24M |
| EBITDA | -27.69M | -15.01M | -12.84M | -15.22M | -12.72M |
| Net Income | -15.38M | -14.73M | -13.04M | -10.75M | -9.50M |
Balance Sheet | |||||
| Total Assets | 29.56M | 24.48M | 21.31M | 15.21M | 23.31M |
| Cash, Cash Equivalents and Short-Term Investments | 16.73M | 16.50M | 9.45M | 8.46M | 16.37M |
| Total Debt | 4.78M | 3.26M | 319.07K | 86.93K | 165.27K |
| Total Liabilities | 8.18M | 6.15M | 1.62M | 1.80M | 1.57M |
| Stockholders Equity | 21.37M | 18.34M | 19.70M | 13.41M | 21.74M |
Cash Flow | |||||
| Free Cash Flow | -17.57M | -7.59M | -16.96M | -8.73M | -9.52M |
| Operating Cash Flow | -17.56M | -7.56M | -16.95M | -8.70M | -9.52M |
| Investing Cash Flow | -9.29K | -38.02K | -8.16K | -36.60K | -2.94K |
| Financing Cash Flow | 17.80M | 14.65M | 17.95M | 824.62K | 12.42M |
Actinogen Medical Technical Analysis
Neutral
0.04
Price Trends
0.04
Positive
0.04
Positive
0.04
Negative
Market Momentum
<0.01
Positive
46.52
Neutral
16.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ACW, the sentiment is Neutral. The current price of 0.04 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.04, and below the 200-day MA of 0.04, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 46.52 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:ACW.
Actinogen Medical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | AU$2.66B | 129.19 | 6.03% | ― | -68.00% | -86.31% | |
52 Neutral | AU$5.95M | -1.56 | 80.84% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$156.60M | -9.17 | -103.42% | ― | ― | 5.88% | |
46 Neutral | AU$111.44M | -6.34 | -30.19% | ― | ― | -16.21% | |
46 Neutral | AU$25.72M | -4.08 | -19.10% | ― | ― | -10.32% | |
45 Neutral | AU$66.98M | -17.83 | -68.12% | ― | ― | 29.55% |
* Healthcare Sector Average
AU:ACW
Actinogen Medical
0.04
0.01
51.72%
AU:ENP
Tryptamine Therapeutics
0.04
<0.01
20.59%
AU:NEU
Neuren Pharmaceuticals Limited
20.45
1.44
7.57%
AU:ATH
Alterity Therapeutics
0.52
-0.18
-25.71%
AU:ZLD
Zelira Therapeutics
0.50
0.05
11.11%
AU:NSB
Neuroscientific Biopharmaceuticals Ltd.
0.06
-0.12
-65.56%
Actinogen Medical Corporate Events
Actinogen Medical Seeks ASX Quotation for 3.6 Million New Shares
Aug 28, 2026
Actinogen Medical Limited has applied for quotation on the ASX of 3,582,562 new ordinary fully paid shares, to be issued on 28 August 2026 under its ACW ticker. The move increases the company’s quoted share capital and reflects the conversio...
Actinogen director increases shareholding through option exercise
Aug 28, 2026
Actinogen Medical has reported a change in director Dr George Morstyn’s interests, following the exercise of unlisted options into fully paid ordinary shares. The transaction involved converting 307,269 unlisted options, exercisable at $0.03...
Actinogen Director Increases Equity Stake Through Option Exercise
Aug 28, 2026
Actinogen Medical has disclosed a change in interests held by director Dr Geoffrey Brooke, following the exercise of previously granted unlisted options. Dr Brooke converted 275,331 unlisted options into an equal number of fully paid ordinary shar...
Actinogen Medical Seeks ASX Quotation for 6.9 Million New Shares
Aug 28, 2026
Actinogen Medical has applied for quotation on the ASX of 6,866,235 additional ordinary fully paid shares, with an issue date of August 28, 2026. The new securities arise from the exercise or conversion of existing options or other convertible ins...
Actinogen Medical Updates Corporate Governance Framework to Align with ASX Standards
Aug 27, 2026
Actinogen Medical has issued an updated Corporate Governance Statement outlining how its board manages and oversees the company on behalf of shareholders. The statement confirms adoption, where practical for its size and nature, of the ASX Corpora...
Actinogen readies pivotal Alzheimer’s data as R&D spend climbs
Aug 27, 2026
Actinogen has reported its FY2026 results, highlighting that its pivotal XanaMIA trial in Alzheimer’s disease remains on track for topline data in November following positive independent monitoring reviews. The company also commenced an open...
Actinogen Director Boosts Shareholding Through Option Exercise
Aug 20, 2026
Actinogen Medical has reported a change in director interests following the exercise of options by board member Dr George Morstyn. The transaction involved converting 299,805 unlisted options into fully paid ordinary shares, modestly increasing hi...
Actinogen Medical Seeks ASX Quotation for 5.9 Million New Shares
Aug 20, 2026
Actinogen Medical Limited has lodged a new application with the ASX for the quotation of additional ordinary fully paid shares. The filing covers 5,914,852 ACW securities, which are to be admitted to trading as part of the company’s existing...
Actinogen Director McComas Exercises Options to Boost Shareholding
Aug 17, 2026
Actinogen Medical has reported changes in the relevant interests of director Malcolm McComas following the exercise of unlisted options. Through related entities Bunyula Super Pty Ltd and McComas Capital Pty Ltd, McComas converted a total of 200,6...
Actinogen Medical Seeks ASX Quotation for 3.2 Million New Shares
Aug 17, 2026
Actinogen Medical has applied to the Australian Securities Exchange for quotation of 3,198,135 new ordinary fully paid shares, issued on 17 August 2026. The securities result from the exercise or conversion of existing options or other convertible...
Actinogen steps up Alzheimer’s push with expert science forum as key Xanamem trial nears data
Aug 11, 2026
Actinogen Medical will host a Clinical Trials Science Forum webinar today, featuring leading Alzheimer’s experts to discuss evolving diagnostic and treatment paradigms, real-world experience with anti-amyloid drugs, and physician expectation...
Actinogen Medical Tightens Trading Rules With New Governance Policy
Aug 10, 2026
Actinogen Medical has adopted a Securities Trading Policy that sets out when directors, senior management and employees may trade in the company’s securities and in securities of other listed entities. The policy reinforces that trading rule...
Actinogen Medical Seeks ASX Quotation for Additional Shares
Aug 10, 2026
Actinogen Medical Limited has applied for quotation of an additional 41,014 ordinary fully paid shares on the ASX. The new securities, with issuer code ACW, are scheduled to be issued on August 10, 2026.The modest increase in quoted shares reflect...
Actinogen Medical Cancels 1.67 Million Shares Under Employee Buy-Back
Aug 9, 2026
Actinogen Medical has announced the cessation of 1,666,666 ordinary fully paid shares following their cancellation under an employee share scheme buy-back. The adjustment to its issued capital reflects routine management of equity-based compensati...
Actinogen Medical Seeks ASX Quotation for 3.5 Million Incentive Shares
Aug 5, 2026
Actinogen Medical Limited, an ASX-listed biotechnology company trading under the ticker ACW, operates in the healthcare and life sciences sector, offering exposure to investors seeking innovative medical development plays. Its ordinary fully paid ...
Actinogen to Host Alzheimer’s Treatment Forum as Xanamem Program Advances
Aug 5, 2026
Actinogen Medical will host a Clinical Trials Science Forum webinar on 12 August to explore the future of Alzheimer’s diagnosis and treatment with leading specialists, including its Chief Medical Officer and internationally recognized neurol...
Actinogen advances pivotal Alzheimer’s trial as regulatory pathway and cash runway strengthen
Jul 30, 2026
Actinogen Medical reported steady progress in its pivotal XanaMIA phase 2b/3 trial in Alzheimer’s disease, which remains fully enrolled and on track for topline results in November, supported by a third positive safety recommendation from th...
Actinogen Medical Seeks ASX Quotation for New Share Issue
Jul 28, 2026
Actinogen Medical Limited has applied to the Australian Securities Exchange for quotation of 340,002 new ordinary fully paid shares under the code ACW. The securities, issued on 28 July 2026, arise from the exercise of options or conversion of oth...
Actinogen Medical Announces Employee Share Scheme Buy-Back
Jul 13, 2026
Actinogen Medical Ltd., an ASX-listed biotechnology company trading under the ticker ACW, has disclosed a buy-back involving its ordinary fully paid shares. The move is tied to its employee share scheme, underscoring the firm’s reliance on e...
Actinogen highlights biomarker-driven progress in pivotal Xanamem Alzheimer’s trial
Jul 12, 2026
Actinogen Medical has showcased new data from its fully enrolled XanaMIA phase 2b/3 trial of Xanamem in mild to moderate Alzheimer’s disease at the Alzheimer’s Association International Conference in London. The company highlighted tha...
Actinogen boosts director equity with new Employee Share Plan issue
Jun 24, 2026
Actinogen Medical has disclosed a change in director Dr Geoffrey Brooke’s interest following the issue of 9 million fully paid ordinary shares to him under the company’s Employee Share Plan. The new allocation, approved by shareholders...
Actinogen Medical Seeks ASX Quotation for 56 Million New Shares
Jun 24, 2026
Actinogen Medical has applied to the ASX for quotation of 56,000,000 new ordinary fully paid shares under its code ACW, with an issue date of June 24, 2026. The move expands the company’s quoted share capital and may enhance its access to eq...
Actinogen shareholders back all resolutions as Xanamem trials advance
Jun 23, 2026
Actinogen Medical reported that all five resolutions put to shareholders at its general meeting were passed as ordinary resolutions by poll. The meeting outcomes reinforce board and investor backing as the company advances its late-stage XanaMIA P...
Actinogen Medical Seeks ASX Quotation for New Share Issue
Jun 18, 2026
Actinogen Medical Limited has applied for quotation on the ASX of 3,147,358 ordinary fully paid shares, to be issued on 18 June 2026 under the ticker ACW. The new securities arise from the exercise or conversion of existing options or other conver...
Actinogen clears third safety review in pivotal Alzheimer’s trial
Jun 17, 2026
Actinogen Medical said an independent Data Monitoring Committee has, for the third time, recommended that its 247-patient XanaMIA phase 2b/3 pivotal trial in mild to moderate Alzheimer’s disease continue without amendment, following a review...
Actinogen wins aligned EMA and FDA backing for Xanamem Alzheimer’s path
May 28, 2026
Actinogen Medical has secured positive scientific advice from the European Medicines Agency for its Alzheimer’s program, aligning closely with prior guidance from the U.S. FDA and clarifying the path to potential marketing approvals in both ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.